10.6084/m9.figshare.12278249.v6 Monique Andersson Monique Andersson eleanor barnes eleanor barnes Tom Beneke Tom Beneke Derrick Crook Derrick Crook Louise Downs Louise Downs David Eyre David Eyre Heli Harvala Heli Harvala William James William James Anita Justice Anita Justice Paul Klenerman Paul Klenerman Sheila F. Lumley Sheila F. Lumley Philippa Matthews Philippa Matthews Anna McNaughton Anna McNaughton Alexander J. Mentzer Alexander J. Mentzer Rutger J. Ploeg Rutger J. Ploeg Jeremy Ratcliff Jeremy Ratcliff David Roberts David Roberts Malcolm G. Semple Malcolm G. Semple Nicole Stoesser Nicole Stoesser Lance Turtle Lance Turtle Maria Zambon Maria Zambon SARS-CoV-2 RNA in blood figshare 2020 COVID-19 SARS-CoV-2 RNA Blood Serum Prevalence Study PCR viraemia Medical Infection Agents (incl. Prions) Medical Microbiology not elsewhere classified Medical Virology 2020-06-24 07:55:32 Dataset https://figshare.com/articles/dataset/SARS-CoV-2_RNA_in_blood/12278249 <p><a></a>This dataset provides supplementary material for a report of the prevalence of SARS-CoV-2 RNA in blood and blood products.</p><p><br></p><p> </p><p><b>Extended Data File 1: Metadata table providing data for prevalence of SARS-CoV-2 RNA in blood and blood products based on a systematic literature review. </b>Details of 28 citations are presented, and the 22 studies included in quantitative meta-analysis are indicated.</p><p><br></p><p> </p><p><b>Extended Data File 2: qRT-PCR quantification of vRNA from sera and viral culture assays.</b> Calculation of vRNA copy numbers, and qRT-PCR results in figure and table format.</p><p><br></p><p> </p><p><b>Underlying Data File 1: Metadata table providing underlying data for serum samples from adults with confirmed SARS-CoV-2 infection, based on RT-PCR nose/throat swab. </b>Sheet 1: samples obtained through patients recruited into a UK clinical cohort at Oxford University Hospitals NHS Foundation Trust (n=212 samples from 167 unique individuals). Cells highlighted in blue show follow-up samples collected from the same individual at different time points. Cells highlighted in orange show serum PCR positives. Sheet 2: samples obtained from convalescent donors a minimum of 28 days post resolution of symptoms, via NHS Blood and Transplant, NHSBT (n=142 samples from 142 individuals).</p><p><br></p><p><b>RT-PCR Primer sequences: </b>provided in a .xlsx file.</p><p><br></p><p><b> </b></p><p><b>PRISMA checklist: </b>reporting for systematic review and meta-analysis</p><p><br></p><p><b> </b></p><p><b>STROBE checklist: </b>reporting for cohort studies</p><p><br></p><p><b>Fig 4A-D:</b> raw, unedited microscope images of cell cultures. Dates of each image stored in the format YYYYMMDD. </p><p>(A) and (B) are controls:</p><p>(A) Negative control Vero E6 cells in media; </p><p>(B) Cytopathic effect (CPE) in Vero E6 cells spiked with Victoria/01/2020 SARS-CoV-2.</p><p>(C) and (D) are Vero E6 cells inoculated with 1/10 dilution of serum sample from sample VC12 (patient ID UKCOV040), that tested positive for SARS-CoV-2 RNA by RT-PCR:</p><p>(C) Aberrant cellular effects at day 4 in a culture inoculated with VC12 at day 0; </p><p>(D) Normal appearance of cells at day 7 inoculated with 1/10 dilution of the culture supernatant of the VC12-challenged culture, illustrated in (C).</p><p><br></p>